Hanson Wade Group’s Post

The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

Virtual sites have the power to transform oncology clinical trials. Science 37 VP of Oncology Dr. Shaalan Beg breaks down what a virtual site is, and how it can deliver better trials for both patients and sponsors in this playbook: https://lnkd.in/eUdCn5P2 #clinicalresearch #clinicaltrials #virtualsite #decentralizedtrials #oncology

https://lnkd.in/gZEzac6Z Key Insights: • Astellas’ acquisition of Propella brings in PRL-02, a groundbreaking androgen biosynthesis inhibitor. This next-gen treatment holds promise in transforming prostate cancer therapy by offering continuous release of abiraterone, aiming for superior efficacy Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #acquisitions #HealthTrends #Insights #HealthIndustry #HealthInnovation #astellas #acquire #propellatherapeutics #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Here is my second publication which published in the Current Pharmaceutical Design journal in 2022. The titled work is: "Preclinical and clinical aspects of using Tazemetostat in human cancers." This review comprehensively examines existing preclinical studies that investigate Tazemetostat as a safe epigenetic agent for treating various cancers. Additionally, it provides a concise summary of the limited clinical evidence available, shedding light on the efficacy of this novel drug in cancer treatment. #epigenetics , #cancertherapy ,

[Clinical Trials] 「FibroGen, Inc. reports phase 1 study results of FG-3246 in metastatic castration-resistant prostate cancer with median radiographic progression-free survival and PSA50 response rates」 ➤ https://lnkd.in/gvX2h7pm [Deals] 「Genmab to Acquire ProfoundBio, Inc. for $1.8B, Gaining Rights to Next-Generation ADCs and Expanding Clinical Trials Portfolio」 ➤ https://lnkd.in/gDYNdT5S 「Kintara Therapeutics, Inc. NASDAQ: KTRA merges with TuHURA Biosciences, Inc. in an all-stock deal, forming a new entity trading as HURA with $31M in subscribed financing」 ➤ https://lnkd.in/gNhsHwFw [Regulatory] 「European Commission expands approval for Bristol Myers Squibb's Reblozyl for first-line treatment of adult patients with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes」 ➤ https://lnkd.in/g5TV38Nh 「FDA approves Vanda Pharmaceuticals' Fanapt for acute treatment of manic or mixed episodes in bipolar I disorder adults」 ➤ https://lnkd.in/gvNpd8Ut

Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda

Check out the latest insights from our #Oncology experts! 👇🏼

On Tuesday 25 June we will host a special webinar tailored for oncology applications. Reserve your spot today: https://lnkd.in/eu__ZVSK Formulators and developers face a significant challenge. During this webinar, we will evaluate stability data of several small molecule drugs for cancer. Degradation and instability in chemotherapeutics can lead to: - Extended development timelines - Regulatory challenges - Compromised product efficacy. This ultimately delays lifesaving treatments for those who need it most - the patients. We will show you how we can optimise oncological drug delivery resulting in long-term formulation stability, extended drug shelf life, and ultimately improved drug performance and efficacy.

TOS) has just completed enrollment for its Phase 2 EVANGELINE clinical trial, evaluating (Z)-endoxifen for ER+ / HER2- breast cancer. Plus, insider buying signals strong confidence in the company's future! 💰 Want to get in on this trade? Check out our recommended buy levels, target prices, and stop loss details. With a potential upside of 27% to 53%, this $1 stock offers 2x to 3x more potential upside than downside! #Investment #StockMarket #AtossaTherapeutics #Biopharma #TradingTips #StrongBuy 

In this episode, I'm in conversation with Manfred Ruediger, CEO of Ariceum Therapeutics, in the Drug Discovery World In Conversation With series of our podcast. Ariceum Therapeutics is focused on developing novel targeted radiopharmaceuticals for the treatment of cancer.